Journal article
An exceptional overall survival using bevacizumab beyond progression in a patient with non-small cell lung cancer
Cancer biology & therapy, Vol.16(12), pp.1720-1725
12/02/2015
DOI: 10.1080/15384047.2015.1095410
PMCID: PMC4847824
PMID: 26418066
Abstract
Non-small cell lung cancer (NSCLC) is the most common malignancy and the leading cause of cancer death worldwide. In this report, we describe a patient with NSCLC who was treated with continuation of Bevacizumab (Bev) beyond progression to first-line Bev-based chemotherapy. The prolonged treatment with Bev by continuing the inhibition of VEGF beyond first-progression has a strong rationale. Nevertheless, few data exist regarding the efficacy and safety of Bev beyond first line of chemotherapy progression in NSCLC patients. Further studies including a large number of patients are needed, in order to select patients who could benefit from this approach.
Details
- Title: Subtitle
- An exceptional overall survival using bevacizumab beyond progression in a patient with non-small cell lung cancer
- Creators
- Giandomenico Roviello - University of SienaEdoardo Francini - Policlinico Umberto IArmando Perrella - University of SienaLetizia Laera - University of SienaMaria Antonietta Mazzei - University of SienaSusanna Guerrini - University of SienaRoberto Petrioli - University of Siena
- Resource Type
- Journal article
- Publication Details
- Cancer biology & therapy, Vol.16(12), pp.1720-1725
- DOI
- 10.1080/15384047.2015.1095410
- PMID
- 26418066
- PMCID
- PMC4847824
- NLM abbreviation
- Cancer Biol Ther
- ISSN
- 1538-4047
- eISSN
- 1555-8576
- Publisher
- Taylor & Francis
- Number of pages
- 6
- Language
- English
- Date published
- 12/02/2015
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985221146902771
Metrics
2 Record Views